DHT

Dược phẩm Hà Tây ·HNX ·2026Q1

▼ Under pressure

Margins remain under pressure Net margin 1.78%, −2.21pp YoY
Price
67,000
Latest close
02 Jun 2026
P/E 137.85x
P/B 5.42x
EPS 486
BVPS 12,365
ROE 3.8%
ROA 2.2%
Profit Margin 1.7%
Asset Turnover 1.34x
Equity Mult. 1.68x

TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity

What Is Changing

On a TTM 2026Q1 basis, DHT is holding revenue at an acceptable level, but margins are eroding visibly — margins have been compressing consistently over multiple periods. What is still missing is better cost control to prevent margin pressure from spreading to the overall profit result.

TTM REVENUE
VND 2,475bn
+19.2%YoY
NET MARGIN
1.78%
−2.2ppYoY
TTM NET PROFIT
VND 44bn
−46.8%YoY
Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24 Q4'23 Q3'23 Q2'23
Revenue 568.8 692.9 638.8 574.4 496.0 542.4 544.5 493.8 505.7 474.2 478.8 547.1
Growth -18% +8% +11% +16% -9% -0% +10% -2% +7% -1% -12%
Net Income 9.0 10.2 11.5 13.4 23.9 20.4 20.3 18.4 16.2 16.8 18.7 26.0
Net Margin 1.58% 1.47% 1.80% 2.33% 4.82% 3.75% 3.72% 3.73% 3.19% 3.55% 3.91% 4.74%

Drivers of DHT's profit

TTM

Net profit attributable to parent declined vs last year, mainly due to lower gross profit. Supporting and offsetting drivers:

Tax ↓ 10.2bn
Gross profit ↓ 35.4bn
Selling expenses ↑ 14.2bn
TTM

Net profit attributable to parent declined vs prior quarter, mainly due to lower gross profit. Supporting and offsetting drivers:

Administrative expenses ↓ 8.4bn
Tax ↓ 3.8bn
Minority interests ↓ 2.7bn
Gross profit ↓ 17.4bn
Selling expenses ↑ 5.2bn
Financial income ↓ 3.1bn

Financial Highlights

Detailed analysis of each financial dimension

ROE = Profit Margin × Asset Turnover × Equity Multiplier

2025Q1 7.8% = 4.0% × 1.09 × 1.79
2026Q1 4.0% = 1.8% × 1.34 × 1.68

ROE fell from 7.8% to 4.0% — leverage weakened the most, though asset turnover still provided support.

Net margin: 1.8% -2.2pp Asset turnover: 1.34x +0.25x Leverage: 1.68x -0.11x

Is the profit sustainable?

Margins are under pressure while earnings still rely significantly on non-core sources.

very positive positive stable watch under pressure

What is driving the margin?

Net margin fell to 1.78%, losing 2.2pp. The main pressure is Gross margin fell 3.2pp, outweighing the improvement in SG&A / Revenue fell 0.5pp (with additional support from Net financial result / Revenue rose 0.1pp and Other profit / Revenue rose 0.0pp).

The pressure comes from core operations — this is a concerning type of decline, not a one-off movement.

Profitability trend

Net Margin 1.78% −2.2pp
Gross Margin 7.75% −3.2pp
SG&A / Revenue 6.68% −0.5pp
Non-core / Revenue 0.95% +0.1pp

TTM YoY · 2025Q1 -> 2026Q1

Watchpoints

Other income is supporting margin

Margin support from other income remains high (42.5% of PBT) — sustainability should be monitored.

Is capital being used efficiently?

Capital efficiency is declining — check whether the drag is from margins or turnover.

Is capital being deployed efficiently?

ROIC fell to 2.28%, losing 2.9pp. That translates to 2.28 in after-tax operating profit for every 100 units of operating capital. The main pressure came from NOPAT margin narrowed 2.3pp, outweighing the movement in capital turnover; with invested capital holding roughly steady.

Pressure came from the margin side — core operations are weakening, not just a temporary asset-management issue.

Watchpoints

ROIC remains low

ROIC is currently 2.28% — below the typical cost-of-capital threshold; worth tracking whether upcoming periods can rise above this level.

CAPITAL EFFICIENCY TREND

TTM YoY · 2025Q1 -> 2026Q1

ROIC 2.28% −2.9pp
NOPAT Margin 1.26% −2.3pp
Capital Turnover 1.80x +0.32x
Average Invested Capital 1,372.3bn −31.6bn

Balance Sheet

ROIC declined — the balance sheet shows how capital is being deployed. Capital structure is conservative with low leverage — liabilities at 0.74x equity, net debt at 0.15x equity.

Inventory ended the period at 513.4bn, roughly 26.6% of total assets.

Over the last 12 months, working capital released 109.3bn of cash, mainly thanks to lower inventories. Pressure from higher receivables and lower payables only partly offset that benefit.

Working Capital Drivers

TTM YoY · 2025Q1 -> 2026Q1

Receivables increased → lower CFO: −9.6bn
Inventories decreased → higher CFO: +167.4bn
Payables decreased → lower CFO: −48.6bn

Working Capital Efficiency

Working capital is being managed more efficiently, supporting overall capital efficiency. Cash conversion cycle improved by 14.3 days versus the same period last year. The main moves came from DIO fell 21.2 days, DSO fell 1.9 days, and DPO fell 8.8 days.

Improvement comes mainly from faster inventory turnover — watch whether this trend persists in coming periods.

Working Capital Efficiency

TTM YoY · 2025Q1 -> 2026Q1

Receivables 15.9 days −1.9 days
Inventory 75.3 days −21.2 days
Payables 32.6 days −8.8 days
Cash Conversion Cycle 58.6 days −14.3 days

Is financial risk significant?

Financial risk is low — leverage is safe, both CFO and FCF are positive.

Leverage & Liquidity

Leverage is balanced for now, with net debt / equity at 0.15x and interest coverage at 2.07x.

At present, short-term debt accounts for 73.0% of total debt, cash equals 45.0% of debt, and total debt stands at 307.6bn.

Watchpoints

Short-term refinancing pressure is meaningful

Short-term debt accounts for 73.0% of total debt, raising near-term refinancing needs.

Leverage and liquidity trend

Net Debt / Equity 0.15x −0.20x
Interest Coverage 2.07x −2.75x
Cash / Debt 45.0% +30.5pp
Short-term Debt / Total Debt 73.0% −4.9pp
CFO / NI 3.90x +3.91x

TTM YoY · 2025Q1 -> 2026Q1

Cash Flow

With safe leverage noted above, cash flow below shows the self-funding capacity. Operating cash flow reached 225.7bn in 2025, against investing cash flow of -94.5bn.

Post-investment cash flow was positive +131.2bn. Financing cash flow was negative +137.1bn.

CFO / net income was 3.90x.

After spending +37.6bn on fixed-asset investment, the business generated trailing free cash flow of +123.8bn.

Cash Conversion

TTM Cash Conversion · 2025Q1 -> 2026Q1

CFO TTM 161.4bn +162.1bn
Cash Capex 37.6bn −23.5bn
FCF TTM +123.8bn +185.6bn

Investment Takeaway

The business is heading the right way, but the current picture is still at partial confirmation — not yet a fully clean case. The positive points have clearly improved, showing the operating base is better than before. The brighter spot is cash generation. The next item to monitor is the earnings mix, when non-core contribution is 14.5%. The main risk still sits in core profitability, with net margin down 2.2 pp.

Improvement: cash generation is recovering, with trailing-12M FCF improving by 185.6bn versus the same period last year.

Watchpoint: cash flow is currently keeping pace with accounting earnings, with CFO / net income at 3.90x. Even so, net financial result still accounts for 14.5% of PBT, so the earnings mix still needs monitoring.

Key risk: profitability remains under pressure, with trailing-12M net margin at 1.78% after a 2.2pp decline versus the same period last year.

Statement Data

Item 2025 2024 2023 2022 2021
Net Revenue
2,402.0 2,086.4 1,999.3 1,837.4 1,609.4
Cost of Goods Sold
2,192.9 1,866.5 1,796.0 1,650.1 0.0
Gross Profit
209.2 219.8 203.3 187.3 154.0
Financial Expenses
19.8 20.1 23.7 16.4 -14.1
Selling Expenses
36.6 30.1 27.2 23.6 -25.9
General and Administrative Expenses
131.9 113.2 76.9 61.2 -66.1
Operating Profit
58.5 82.7 99.3 114.1 80.7
Profit Before Tax
73.3 95.2 110.3 123.2 89.5
Net Income
59.0 75.2 89.0 99.0 71.4
Profit Attributable to Parent
53.7 71.8 85.1 95.2 67.9
Earnings per Share
645.00 872.00 1,682.00 3,604.00 2,572.83

Explore Other Stocks In The Same Sector

DHG, DVN, IMP, DBD, DTP, TRA, DMC, DP3, OPC, NDC, DAN, PMC, VDP, FIT, DHD, AGP, DVM, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, MED, DBT, DTG, DPP, BIO, VNY, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP

Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.